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Host-microbe interactions at the gastrointestinal interface have emerged as a key component in the gov-
ernance of human health and disease. Advances in micro-physiological systems are providing research-
ers with unprecedented access and insights into this complex relationship. These systems combine the 
benefits of microengineering, microfluidics, and cell culture in a bid to recreate the environmental con-
ditions prevalent in the human gut. Here we present the human-microbial cross talk (HuMiX) platform, 
one such system that leverages this multidisciplinary approach to provide a representative in vitro mod-
el of the human gastrointestinal interface. HuMiX presents a novel and robust means to study the mo-
lecular interactions at the host-microbe interface. We summarize our proof-of-concept results obtained 
using the platform and highlight its potential to greatly enhance our understanding of host-microbe 
interactions with a potential to greatly impact the pharmaceutical, food, nutrition, and healthcare 
industries in the future. A number of key questions and challenges facing these technologies are also 
discussed.
© 2017 THE AUTHORS. Published by Elsevier LTD on behalf of the Chinese Academy of Engineering and 








Microorganisms, comprising bacteria, archaea, and microeu-
karyotes, represent the smallest living organisms on the planet. 
Despite their small size, they play a crucial role in the gover nance 
of numerous systems, including the human body. In terms of 
numbers, the abundance of bacterial cells inside and on the hu-
man body are thought to be of the same order of magnitude as 
the number of human cells that actually make up the body [1]. 
Human microbiota colonize the surfaces of different human tis-
sues. The majority resides within the gastrointestinal tract (GIT), 
where it is the main constituent of this extremely diverse and dy-
namic ecosystem. The status of this system depends on a myriad 
of factors, including host genetics, immune status, and diet [2]. 
Numerous studies have highlighted the key role that the gas-
trointestinal microbiome plays in processes such as digestion, nu-
trition, metabolism, and, most importantly, in the pathogenesis of 
disease [3–7]. More specifically, modern high-resolution molecu-
lar analyses have implied a link between dysbiosis (a disequilibri-
um in the microbial ecology of the GIT) and a range of idiopathic 
diseases, including obesity [8], diabetes [9], colorectal cancer [10], 
neurological conditions [11], and allergies [12]. One key method 
is metagenomics, which involves the sequencing of genomic DNA 
extracted from the gut microbiome. This method provides a rapid 
and precise means of taxonomy and identification of individual 
microbes within the gut. Besides metagenomics, functional omic 
approaches, such as metatranscriptomics, metaproteomics, and 
metabolomics, provide qualitative and quantitative information 
on transcripts, proteins, and metabolites present in microbial 
communities at specific points in space and time [13–15]. These 
meta-omic analyses provide a useful means of identifying, quan-
tifying, and functionally characterizing the microbes present 
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within the gut. However, to causally link the identified differences 
in the human microbiota with distinct human diseases, experi-
ments allowing the testing and validation of results derived from 
meta-omics studies are essential [16]. In other words, beyond 
associations derived from analyses of samples collected in vivo, it 
is now critical to develop a detailed mechanistic understanding of 
the fundamental molecular mechanisms at play in host-microbe 
interactions and their role in immune regulation, infection, and 
metabolism.
While it is possible to study host-microbe interactions in vivo 
using animal models [17] and in vitro, for example using Tran-
swell systems [18], it has been well established that these models 
are not physiologically representative of the conditions within 
the human GIT [19]. In addition, animal models are very costly, 
both from financial and temporal standpoints [20]. Hence, there 
is a significant need to develop in vitro solutions that recreate the 
physiological conditions present inside the human GIT for rapid, 
reproducible, and high-throughput experimentation.
Recent advances in microengineering, biomaterials, and elec-
tronics have provided an alternative means to study molecular in-
teractions at the gastrointestinal human-microbe interface. More 
specifically, by applying the microfabrication techniques devel-
oped for the semiconductor and electronics industries to fluidic 
automation, it is now possible to construct in vitro systems that 
more closely approximate those conditions present within the 
gut and other organs on scales identical to those encountered in 
vivo. Such platforms are referred to as an “organ-on-a-chip,” and, 
when seeded with the relevant host cells, make use of microflu-
idics to mimic the specific physiological conditions seen in vitro. 
These microfluidics-based systems offer numerous advantages 
over traditional cell-culturing techniques, including a 3D culture 
environment, provisions for long-term experiments, greater ex-
perimental flexibility, the ability to deliver nutrients and other 
chemical cues to cells in a controlled manner, much-reduced re-
agent requirements, the ability to precisely tune spatiotemporal 
oxygen and pH gradients, low shear environments, and the ability 
for high-throughput experimentation. 
A number of microfluidics-based in vitro intestinal models 
have been developed. These involve the culture of human intes-
tinal epithelial cells in hydrogels [21], in polydimethylsiloxane 
(PDMS)-based chips [22,23], or on polyamide membranes [24]. 
However, these systems are not representative of the in vivo sit-
uation, as they fail to reproduce the dynamic microenvironment 
of the intestine—most notably, the distinct flow regimes that 
are prevalent at the human-microbe interface. In addition, these 
approaches fail to recreate the anaerobic conditions for culturing 
representative bacterial species from the gut (they only allow the 
culturing of aerobically growing probiotic strains); they do not 
provide a constant supply of nutrients to the basal interface of the 
epithelial cells, as is the case in vivo through arterial blood sup-
ply; and they are not modular, thereby not allowing rapid extrac-
tion of the cells post co-culture for detailed molecular analyses 
[25]. The following section presents the human-microbial cross 
talk (HuMiX) platform, a modular microfluidics-based human- 
microbial co-culture system. This platform overcomes a number 
of the limitations of the previously described in vitro models and 
provides a more representative model of the human gastrointes-
tinal-microbe environment, as validated by an extensive suite of 
proof-of-concept experiments.
2. Human-microbial cross talk (HuMiX)
The HuMiX platform (Fig. 1) [25] consists of three parallel mi-
crofluidic channels. These stacked and aligned channels act as mi-
crochambers, and are referred to as the microbial, epithelial, and 
perfusion microchambers, respectively (Fig. 1(c)). Each chamber 
has dedicated inlets and outlets, which allow for the inoculation 
of the relevant cell lines and the precise control of the physi-
ochemical conditions within each microchamber through the 
perfusion of dedicated cell growth media. Furthermore, the ded-
icated outlets allow for the collection of eluates from the individ-
ual chambers for subsequent analyses. The channels (200 mm × 
4 mm × 0.5 mm) are laser cut from polymer gaskets and fol-
low a distinct spiral pattern that optimizes the footprint of the 
system. The channels are separated from one another by semi- 
permeable polycarbonate membranes. The pore sizes of the 
membranes (50 nm and 1 µm) are distinct according to their 
particular function. The 50 nm pore size membrane separates the 
microbial and epithelial chambers and prevents infiltration of 
microorganisms into the epithelial chamber, while the 1 µm pore 
size membrane separates the perfusion chamber from the epi-
thelial chamber and allows diffusion of the cell growth medium 
to the epithelial chamber (Fig. 1(c)). In addition, the membranes 
are coated with mucin (50 nm pore size membrane) and collagen 
(1 µm pore size membrane) during co-culture, which aids in the 
adherence of the cells to the membranes. During incubation, 
Dulbecco’s Modified Eagle Medium (DMEM) is perfused through 
the microbial and perfusion chambers via a peristaltic pump 
to simulate the peristaltic motions and intraluminal fluid flow 
present within the gut, thereby creating an environment that is 
Fig. 1. The HuMiX platform [25]. (a) Image of the assembled HuMiX platform (the scale bar is equivalent to 1 cm); (b) exploded view of the HuMiX platform; (c) annotated 
schematic illustration of the key features in the HuMiX platform.
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ing a particular co-culture regimen. This allows for the extraction 
of the intracellular biomolecules from the cultured cells, and the 
obtained DNA, RNA, and protein fractions are subsequently sub-
jected to high-resolution omic analyses [26]. The viability of the 
co-cultured cells was determined via fluorescence microscopy 
(Fig. 2(c) and (d)), and such analyses demonstrated that no cyto-
toxic effects were induced in either cell contingents following 24 h 
of co-culture. Visible differences in the eluates from the three 
chambers support the hypothesis of distinct microenvironments 
within each chamber (Fig. 2(e)). The simultaneous and continu-
ous perfusion of both oxic (21% dissolved O2) and anoxic (0.1% dis-
solved O2) DMEM through the perfusion and microbial chambers, 
respectively, allows for the establishment and maintenance of the 
oxygen gradients present in vivo. The measured levels, 5.43% ± 
0.14% and < 0.8%, are comparable to those recorded in human 
intestinal tissues (i.e., approximately 4.6% [27]), and in the lumen 
(i.e., approximately 0.2% [28]), respectively. The data in Fig. 2 [25] 
illustrates the ability of HuMiX to successfully co-culture human 
and microbial cells in an environment similar to that encoun-
tered within the GIT. To further demonstrate the validity of the 
platform, studies were performed with additional bacterial and 
human cell inocula, most notably Bacteroides caccae (B. caccae) 
and CCD-18Co, respectively. Furthermore, co-culturing was also 
performed with primary CD4+ T cells present within the perfusion 
microchamber. More explicit details of these studies, including 
results, can be found in Ref. [25]. While the results demonstrate 
the capability of HuMiX to successfully co-culture different hu-
man cell types and microbial cells, it is worth noting that individ-
ual cell types only partially represent the complexity of the whole 
gastrointestinal tissue. 
As part of our proof-of-concept experiments, we established 
different culture regimes to determine if HuMiX-based cellular 
read-outs were in agreement with previous in vivo data. Our 
results demonstrate a high degree of congruence between the 
representative of a healthy intact epithelial barrier. The environ-
ment within the device is routinely monitored through a series of 
non-invasive oxygen sensors, while the cell growth and differen-
tiation within the device are measured using the standard tran-
sepithelial electrical resistance (TEER) measurement electrode, 
which can be inserted into the device. A more detailed descrip-
tion of the platform and its operating parameters can be found in 
Ref. [25]. The following section details the co-culture of human 
and bacterial cells within the HuMiX platform and illustrates the 
ability of HuMiX to successfully recreate the microenvironment 
that exists within the human GIT.
2.1. Proof of concept
To validate the ability of HuMiX to successfully co-culture 
human and microbial cells and to establish environmental con-
ditions closer to those prevalent in the human GIT, the epithelial 
chamber was inoculated with the human epithelial colorectal ad-
enocarcinoma cell line Caco-2, while the microbial chamber was 
inoculated with the probiotic Lactobacillus rhamnosus GG (LGG). 
The human cells grew on the collagen-coated microporous mem-
brane and were supplied from their basal side with oxygen-rich 
DMEM via the perfusion chamber, thereby fluidically mimicking 
the arterial blood supply and providing a shear-free environment 
in the epithelial microchamber for the cells to grow. The differ-
entiation of the epithelial cells was evaluated by measuring the 
TEER of the Caco-2 cell layer (Fig. 2(a)) [25], and through micro-
scopic observation (Fig. 2(b) and (c)). Once a confluent cell layer 
was established (this typically occurs six days after inoculation), 
the microbial chamber was seeded with anaerobically grown LGG 
bacterial cells. The microbial chamber was perfused with bacte-
rial culture medium, in which the O2 concentration was reduced 
to below 1% by N2 gas. Importantly, the modular architecture of 
HuMiX facilitates access to the individual cell contingents follow-
Fig. 2. Data illustrating the ability of the HuMiX platform to sustain the co-culture of human and microbial cells [25]. (a) TEER measurements of the epithelial cell 
layer formed in HuMiX benchmarked against measurements from a standard Transwell system with error bars indicating the standard error of the mean (n = 3); 
(b) immunofluorescent microscopic image of the tight junction protein occluding (green) in Caco-2 cells following 24 h of co-culture with LGG grown under anaerobic con-
ditions (the cell nuclei are stained with 4,6-diamidino-2-phenylindole and appear in blue); (c) fluorescent microscopic image of the live-dead stain of the Caco-2 cells 24 h 
post-culture; (d) fluorescent microscopic image of the live-dead stain of the LGG 24 h post-culture (the live cells appear in green whereas dead cells appear in red, and 
the scale bar is equivalent to 10 µm); (e) sample eluates from the three separate microchambers in HuMiX following 24 h of co-culture; (f) dissolved oxygen concentration 
levels (%) present within the perfusion and microbial chambers following inoculation of LGG (◆ denotes pre-inoculation levels in the microbial chamber).
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HuMiX experiments and previous in vivo data obtained from both 
humans and animals [25], thus further illustrating the validity of 
the HuMiX platform as a representative model of the gastrointesti-
nal human-microbe interface. Furthermore, interesting differenc-
es in terms of cellular responses were observed under different 
experimental conditions. More specifically, several molecular 
hallmarks of the co-cultured human cells were found to be signif-
icantly altered following their co-culture with LGG growing under 
anaerobic conditions. These included a reduction in the expres-
sion of pro-inflammatory cytokines (e.g., CCL20 and IL-8), differ-
ential expression of genes of known relevance in the context of 
gastrointestinal cancers (e.g., Sox4 and TPD52), miRNAs with so- 
far unknown functions but previously found to be of interest in 
the context of cancer research (e.g., miR 483-3p and miR 1229-
3p), and increases in the abundance of tricarboxylic acid (TCA) 
cycle intermediates (e.g., fumarate and citrate), which suggest a 
role for the microbiome in regulating primary energy metabolism 
(Fig. 3). 
The results summarized here and presented in Ref. [25] illus-
trate the capability of HuMiX to establish physiological conditions 
similar to those present within the human GIT and provide a 
means to further our understanding of the fundamental mech-
anisms at play in host-microbe interactions. The flexibility and 
robustness of the platform allow it to mimic a plethora of host- 
microbe interactions that occur within the gut. As such, the plat-
form has the potential to be used in a variety of application areas, 
especially those with relevance to the pharmaceutical, food, and 
nutrition industries.
The following subsections provide examples of how the platform 
will be used in the future to study the immunological response 
of the host to commensal microorganisms/pathogens present 
within the gut, as well as to determine the effects of diet (via dif-
ferent combinations of prebiotics and probiotics) on host-microbe 
dynamics, particularly within the context of disease.
2.2. Immuno-HuMiX
The intestinal microbiota is in a constant, homeostatic relation-
ship with the immune system of the gut, and disruption of this 
balance has been implicated in disease pathogenesis [29]. Thus, 
the establishment of cause-effect relationships in the complex in-
teractions between the gut microbiota, the intestinal epithelium, 
and the immune system are a crucial step in the development of 
successful microbiome-based strategies for maintaining human 
health. Based on our initial co-culture experiments using CD4+ T 
cells [25], we are now expanding the HuMiX platform to analyze 
the interactions between the immune system and the intestinal 
microbiota in the human gut. In the immuno-HuMiX model, we 
will be able to co-culture gastrointestinal microbes, human epithe-
lial cells, and primary human immune cells isolated from healthy 
human volunteers, in three distinct chambers, separated by semi- 
permeable membranes (Fig. 4). The first steps have been undertak-
en to integrate human peripheral blood mononuclear cells (PBMCs) 
isolated from fresh blood from healthy volunteers into the perfu-
sion microchamber, in order to monitor the interplay of bacterial 
and epithelial cells on immune cells, and vice versa. Multiple sub-
sets of CD4+ T cells have been described in the intestine, which rep-
resents an important site for the generation and regulation of cells 
involved in immune responses both within and outside of the GIT. 
Intestinal Th1 and Th17 cell populations are required for adequate 
responses to intracellular bacteria and viruses. We are now investi-
gating the interplay between T cell populations that are important 
in gut immunity, such as Th1 and Th17 cell, and representative gut 
bacterial strains. As such, immuno-HuMiX represents a new ap-
proach to study the microbiome-immune system interaction and 
should greatly enhance our understanding of how individual bac-
terial strains might influence human health and disease.
2.3. Nutri-HuMiX
To understand the role of dietary components and gut bacteria 
on human physiology, a thorough mechanistic understanding of 
the interplay between diet, microorganisms, and human cells is 
required. Being a representative model of the human gastroin-
testinal interface, the HuMiX model is uniquely suited to answer 
these questions, as it allows the co-culture of bacterial strains with 
human intestinal cells for prolonged periods of time under specific 
experimental conditions. To study the effects of dietary compo-
nents on the gut microbiome, in addition to its potential synergis-
tic or additive effects on human physiology, we have successfully 
implemented the HuMiX model to simulate different dietary in-
terventions. For the proof of concept of nutri-HuMiX (Fig. 4), two 
probiotic strains, LGG and B. caccae, were perfused with standard 
illegal efflux medium (SIEM), supplemented with a soy prebiotic 
and co-cultured with human Caco-2 cells in the epithelial chamber. 
Preliminary results show that gene expression patterns in the hu-
man epithelial cell line Caco-2 are altered after 24 h of co-culture. 
More specifically, we found that potential tumour suppressors are 
up-regulated under these conditions, compared with experiments 
in which the cells are supplemented with DMEM alone. We are 
Fig. 3. Examples of genes, miRNAs, and metabolites found to be differentially abundant in Caco-2 cells following 24 h of co-culture with LGG growing under anaerobic 
conditions.
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currently in the process of expanding this study to include dif-
ferent lines of primary colorectal cancer cells—T20 to represent 
stage II colorectal cancer and T18 to represent stage IV colorectal 
cancer—into the nutri-HuMiX platform, with the specific aim of 
examining the effects of different combinations of prebiotics, 
such as fiber, on the cancer cells. The knowledge and information 
garnered from such studies will likely have pronounced impacts 
in the food, biopharmaceutical, and medical fields, further high-
lighting the need and potential for in vitro experiments in plat-
forms such as HuMiX. 
3. Concluding remarks and future challenges
There is an abundance of untapped information within the gut 
microbiome and its effect on the human host. This information 
pertains to the numerous processes and interactions that shape 
human physiology. Over the past decade, significant advances 
in science and engineering have allowed researchers to gain un-
precedented insights into the microbial ecology of the GIT and its 
role in shaping human health and disease. Breakthroughs in bio-
materials, microengineering, and cell culture have resulted in the 
creation of in vitro platforms, such as microfluidics-based devices, 
that provide closer approximations to the environmental condi-
tions present in the gut. 
Platforms such as HuMiX and other organ-on-a-chip devices 
[30–32] have many potential application areas. For example, the 
pharmaceutical industry is under considerable pressure, both 
ethically and economically, to find alternative ways to expedite 
the drug development process and to do so in a safer, more cost- 
effective, and ethically responsible manner. The high failure rates 
associated with the development of new drugs may in part be 
due to the use of non-representative animal models and to the 
lack of consideration for the microbiome in relation to drug me-
tabolism. Other industries facing similar challenges are the food 
and nutrition industries, where the efficacies of certain dietary 
components have yet to be mechanistically proven. There is also 
considerable potential to use the microbiome as a biomarker for 
disease, or to derive modulators that could specifically repair 
dysbiosis within an individual in order to potentially cure disease 
[20]. However, in order to capture the specific dynamics at play in 
a healthy or diseased gut, it is necessary to understand the inter-
actions that drive the gut ecosystem one way or another. As such, 
platforms such as HuMiX, which permit studies on the effects of 
individual bacteria and contingents on host physiology, are cru-
cial to further our fundamental knowledge and understanding. 
Although developed primarily to study the host-microbe inter-
action in the human gut, the unique architecture of HuMiX—its 
ability to co-culture individual cell lines or communities in such 
close proximity, yet completely separately from one another—
also makes it an excellent tool to study fundamental processes 
underlying the microecology of the human gut. For example, the 
ecology of stable communities established within HuMiX could 
be experimentally perturbed, leading to a disequilibria that is 
analogous to dysbiosis. In this way, the transition states could 
be studied in detail, leading to, for example, the development of 
early biomarkers for dysbiosis-linked diseases. 
The use of microfabrication techniques and microfluidics rep-
resents one of the most promising means to recreate the complex 
features of the gastrointestinal human-microbe interface. These 
methods allow for the precise reconstruction of the structure, 
mechanics, and chemical delivery that occur at the cellular level. 
However, there are a number of technical and industrial challeng-
es that still need to be solved in order to better recreate the phys-
ical and chemical environment within the gut. Foremost amongst 
these are better biomaterials. Most current devices are fabricated 
from polymers such as PDMS, due to their biological compatibility 
and rapid prototyping potential. However, PDMS has poor chem-
ical resistance to organic solvents and absorbs small hydrophobic 
molecules, such as drugs and fluorescent dyes, thereby limiting 
its potential use for rigorous experiments; hence, chemical mod-
ifications are required, or other substrate materials need to be 
developed. Further more, from a manufacturing perspective, it is 
difficult to reliably reproduce devices made of PDMS on the large 
scale that is required for clinical validation studies, which require 
scalable, high-throughput systems. Additional engineering chal-
lenges include: the development and integration of sensors that 
can measure and detect the optical, electrical, mechanical, and 
chemical signals from the cells; and the integration of microfluidic 
valves and pumps to more accurately recreate the peristaltic mo-
tion and linked physiological conditions within the gut. Advances 
are also required in microbiological assays and in the inclusion 
of additional cell types, which may, for example, be derived from 
human-induced pluripotent stem cells in order to further ad-
vance our understanding of the host-microbe interactions in both 
a healthy and a diseased gut. 
By combining the disciplines of microfluidics, microbiology, 
and cell biology, a number of questions pertaining to the host- 
microbe interactions in the GIT have been answered. However, 
we are just at the start of an exciting journey and further advanc-
es are required to better replicate the in vivo conditions in vitro. 
These advances are required to leverage the full potential of the 
HuMiX platform and other such platforms in order to provide 
much-needed comprehensive insights into host-microbe molecu-
lar interactions. 
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